Monday, July 18, 2011

Chitosan Curcumin as Cancer Cell Hunter

Herbal medicine development currently have shift the using of synthesize medicine to herbal medicine. The Researchers of Pharmacy Faculty of Gadjah Mada University, Yogyakarta, in 2003 obtained a patent Pentagamavunon-0 in the United States, which is modified curcumin compound inhibiting cancer cells.

Chitosan nanoparticles now being developed to bring curcumin to more effectively targeted to cancer cells.
This (modified curcumin) for anticancer drugs in combination with curcumin in the overlying chitosan nanoparticle size, "says lecturer and researcher at the Pharmacy Faculty of Gadjah Mada University, Ronny Martien, Thursday (23 / 6), after receiving the award and research grant from the Bureau Oktroi and the Indonesian Academy of Sciences (AIPI) in Jakarta.


Ronny is one of four other young researchers who were given grants by the Bureau of research and AIPI Oktroi. Ronny proposed field of research utilization on Biological Diversity.

Research title "Utilization of Chitosan in Improving Bio availability Compound Pentagamavunon-0 (PGV-0) as an Analgesic-antiinflammation drugs with formulations of Nano particles".
PGV-0 is a derivative of an analog of curcumin derived from turmeric and ginger rhizome. According to Ronny, PGV-0 studied GMU in cooperation with the Dutch.

Then, PGV-0 patented in the U.S. Patent Number US-6777. 447B2. This is because there are many curcumin research done in this country and has resulted in several patents as well. Curcumin was obtained from turmeric and ginger are widely exported by Indonesia to the U.S.

PGV-0 proved to have the ability to inhibit the enzyme cyclooxygenase (COX-2) contained in cancer cells. Expression of COX-2 enzyme tends to increase in the cancer cells so it must be inhibited for the healing process. "PGV-0 as an anticancer drug also has drawbacks in the form dissolve level in water is low so it needs to be combined with chitosan that dissolved high in water," said Ronny.

No comments: